C2iTech Limited

1. Cultivation and Cryopreservation of Organoids

C2iTech specialises in cultivating personalised respiratory organoids from non-invasive patient samples. These organoids act as "mini-models" of the respiratory system, enabling:

- Prediction of responses to infections and treatments
- Evaluation of therapy effectiveness
- Assessment of immune defences against respiratory diseases

Our organoids can be cryogenically stored for long-term use, creating a renewable resource for personalised medicine and advancing medical research. With a high success rate in non-invasive sampling, our organoids are invaluable for infectious disease studies and targeted therapeutic development.

2. Novel Respiratory Drug Screening

Our Novel Respiratory Drug Screening service allows pharmaceutical and biotech firms to test drugs and vaccines using organoids that closely mimic human respiratory tissues. This offers more accurate results, accelerating the development of life-saving treatments.

3. Respiratory Virus Research Service

C2iTech provides stable ex vivo research models for government agencies and academic institutions studying respiratory viruses. Our customisable models, derived from diverse donor sources, enable research into viral transmission, pathogenesis, and treatment approaches in relevant human tissue contexts.

Future R&D: Organoid Culture Development and Standardisation

We are developing a proprietary culture medium, Culture Medium 1.0, to enhance organoid growth and functionality. This innovation will optimise experimental models for applications ranging from drug testing to disease modelling.

Organoid Platform Standardisation

C2iTech is dedicated to the standardisation of organoid platforms, a critical step toward enhancing the reliability and translatability of organoid models in preclinical research. By partnering with industry leaders such as JingKe Biotech, we aim to establish comprehensive standard operating procedures (SOPs) for organoid cultivation. This initiative will not only ensure uniformity in organoid production but also facilitate the integration of these models into various therapeutic research applications.

The standardisation process will encompass the development of protocols that cover all aspects of organoid culture, including cell sourcing, media formulation, growth conditions, and characterisation methods. By implementing these SOPs, we will create a framework that allows researchers to replicate results across different labs and studies, thereby improving the quality of data generated from organoid models.

Furthermore, our initiative will prepare the organoid platform for preclinical evaluation, ensuring that these models meet regulatory requirements and are suitable for clinical translation. This preparation is vital for fostering collaboration with pharmaceutical companies and research institutions, thereby enhancing the overall impact of organoid technology in drug discovery and personalised medicine.

Consultancy & Training Services

C2iTech offers scientific consultancy and training workshops in organoid research, equipping participants with hands-on experience and industry-recognised credentials to meet the growing demand for personalised healthcare.